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Abstract
Background: Wnt inhibitory factor-1(WIF-1) acts as a Wnt-antagonists and tumor suppressor, but hypermethylation
of WIF-1 gene promoter and low expression activate Wnt signaling aberrantly and induce the development of
various human tumors. With this work we intended to investigate the expression and promoter methylation status
of WIF-1 gene in human astrocytomas.
Methods: The tissue samples consisted of 53 astrocytomas and 6 normal brain tissues. The expression levels of
WIF-1 were determined by immunohistochemistry and semiquantitative RT-PCR. The results were analyzed in
correlation with clinicopathological data. Methylation status of WIF-1 gene promoter was investigated using
methylation specific PCR. The relationship between methylation and expression of the genes was analyzed.
Results: The average expression levels of WIF-1 protein and mRNA in astrocytomas were decreased significantly
compared with normal control tissues. The protein and mRNA expression of WIF-1 gene in astrocytomas was
decreased with the increase of pathological grade. Furthermore, WIF-1 promoter methylation was observed by MS-
PCR in astrocytomas which showed significant reduction of WIF-1 expression. The WIF-1 promoter
hypermethylation was associated with reduced expression of WIF-1 expression.
Conclusion: Our results demonstrate that the WIF-1 gene is frequently down-regulated or silenced in astrocytomas
by aberrant promoter methylation. This may be an important mechanism in astrocytoma carcinogenesis.
Background
Astrocytomas are the most common primary tumors of
the central nervous system. Despite recent advances in
diagnosis and therapies such as surgery, radiation, and
chemotherapy, the prognosis and survival times of high-
grade astrocytomas(WHO grade III, IV)remains poor.
The median survival is only 12 to 15 months for
patients with glioblastoma(WHO grade IV)and 2 to 5
years for patients with anaplastic astrocytoma(WHO
grade III)[1].
The Wnt/b-catenin signaling pathway plays a signifi-
cant role in various processes of early development and
the pathogenesis of human diseases, including human
malignancies. Recently, there are several reports which
evident the involvement of Wnt/b-catenin signaling in
astrocytomas [2-5]. Wnt inhibitory factor-1 (WIF-1) is
identified as one of the secreted antagonists that can
directly bind to Wnt proteins to inhibit Wnt/b-catenin
signaling[6]. Down-regulation and promoter hypermethy-
lation of WIF-1 gene have been reported in human hepa-
tocellular, nasopharyngeal, pulmonary, urocystic and
gastrointestinal malignancies [7-11]. Yet little is known
regarding the expression and promoter methylation of
WIF-1 in astrocytomas. In this study, we describe for the
first time that the expression of WIF-1 was frequently
downregulated by its promoter hypermethylation in
astrocytomas compared with normal tissue samples,
which might contribute to the upregulation of Wnt/b-
catenin signaling in astrocytoma carcinogenesis.
Materials and methods
Patients and tissue samples
53 fresh astrocytoma samples (T1-T53)were collected
after informed consent from patients who underwent
brain operations for astrocytoma at Xiangya Hospital
(Hunan, China). Immediately after surgical resection,
portions of the tumors were frozen and stored at -80°C
for RNA and DNA extraction, and the remanets were
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fied according to the World Health Organization (2007)
[12], including gradeI(1), grade II(22), grade III(12), and
grade IV(18). In all cases of astrocytomas, there were 32
(60.38%) males and 21 (39.62%) females with the median
age of 38.5 years (range: 5~66 years). For comparison, 6
normal human tissues (N1-N6) from patients with con-
tusion and laceration of brain were obtained at the time
of decompressive operation.
Immunohistochemistry
WIF-1 protein expression was determined by using
immunohistochemical staining (IHC) on formalin-fixed
paraffin-embedded tissue sections. Briefly, 5 μmt h i c k
sections were deparaffinized, rehydrated using xylene
and alcohol, incubated with 0.3% H2O2 to block endo-
genous peroxidase activity, and incubated with normal
goat serum to block nonspecific antibody binding.
Before immunostaining, antigen retrieval was done by
immersing sections in a 10 mM concentration of citrate
buffer (pH6.0) and boiling in a pressure cooker for 2
minutes. The sections were incubated at 4°C overnight
with a 8 μg/ml monoclonal antibody against human
WIF-1 protein (R&D, Minneapolis, USA). The sections
were then incubated with biotinylated goat anti-mouse
IgG antibody (Zymed, San Francisco, CA, USA) for 30
min. The antigen-antibody complexes were visualized
using streptavidin-horseradish peroxidase conjugate
(Zymed, San Francisco, CA, USA) and diaminobenzidine
(DAB)as a chromogen.
The slides were counterstained with hematoxylin. For
WIF-1 protein expression, nuclear staining was consid-
ered to be negative, whereas cytoplasmic and membra-
nous expression was analyzed according to the
intensity and proportion of positive cells to all cells
[10]. IPP6.0 (Media Cybernetics, Bethesda, MD, USA)
was applied to semiquantify immunohistochemical
results. Staining was scored for intensity [0 (negative),
1+ (weak), and 2+ (strong)] and percentage of postive
staining in malignant cells [0 (0-4%), 1 (5-24%),2 (25-
49%), 3 (50-74%), or 4 (75-100%)]. The multiplication
of intensity and percentage counts was used as the
final immunohistochemistry scores [13]. For hetero-
genous staining patterns, each component was scored
independently and the results were summed. For exam-
ple, a specimen containing 25% tumor cells with strong
intensity (1 × 2 + = 2), 25% tumor cells with weak
intensity (1 × 1 + = 1), and 50% tumor cells without
immnoreactivity received a score of 2 + 1 + 0 = 3.
Cytoplasmic and membranous staining in normal brain
tissue served as internal positive controls. Negative
controls were included in the IHC analyses by omitting
the primary antibody.
RNA extraction and Semiquantitative RT-PCR
Total RNA from tumor tissues and normal tissues were
isolated using a TRIzol procedure(Invitrogen, Carlsbuel,
CA, USA). An equal amount of RNA from each sample
was added to 25 μl of reaction mixture and cDNA was
synthesized by First Strand cDNA Synthesis kit (Fer-
mentas, Burlington, Canada). Primers for semiquantita-
tive RT-PCR were obtained from Takaro (Dalian,
China). Primer sequences for the human WIF-1 cDNA
were 5’-CCGAAATGGAGGCTTTTGTA-3’ (forward)
and 5’-TGGTTGAGCAGTTTGCTTTG-3’ (reverse)[8].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
w a su s e da sa ni n t e r n a lc o n t r o l .P r i m e rs e q u e n c e sf o r
GAPDH were 5’-CAATGACCCCTTCATTGACC-3’
(forward) and 5’-TGGAAGATGGTGATGGGATT-3’
(reverse). The cycle was defined at 95°C for 5 min, fol-
lowed by 32 cycles of denaturing at 95°C for 30 sec,
annealing at 56°C for 40 sec and extension at 72°C for
40 sec. This was followed by the final extension at 72°C
for 10 min. The PCR products were electrophoresed in
2% agarose gels. Relative WIF-1 mRNA levels were eval-
uated by UVP software (UVP Inc., Upland, CA, USA)
and were expressed as the fold-difference relative to
GAPDH mRNA levels.
Genomic DNA Extraction and Methylation-specific PCR
(MS-PCR)
DNA was extracted from astrocytoma tissues by standard
proteinase K digestion, phenol chloroform and ethanol
precipitation proceeded. Bisulfite modification of genomic
DNA was carried out by using a EZ DNA methylation
kit (Zymo, CA, USA), according to the manufacturer’s
protocol. WIF-1 promoter region has been identified and
described previously [14]. Bisulfite-treated genomic DNA
was amplified using either a methylation-specific or an
unmethylation-specific primer set. GC Rich DNA poly-
merase (Qiagen, Hilden, Germany) was used in the
experiments. Sequences of the methylation-specific pri-
mers were 5’-GGGCGTTTTATTGGGCGTAT-3’ (for-
ward) and 5’-AAACCAACAATCAACGAAC-3’ (reverse).
Sequences of the unmethylation-specific primers were 5’-
GGGTGTTTTATTGGGTGTAT-3’ (forward) and 5’-
AAACCAACAATCAACAAAAC-3’ (reverse) correspond-
ing to the WIF-1 promoter region sequences -488 to
-468 and -310 to -290, respectively. The PCR was carried
out in a Techne TC-412 Thermal Cycler(Keison, Essex,
UK) under the following conditions: one cycle of 95°C
for 10 min, followed by 35 cycles of denaturing at 94°C
for 1 min, annealing at 60°C for 50 sec and extension at
72°C for 50 sec. This was followed by the final extension
at 72°C for 10 min. The PCR products were analysed by
electrophoresis on 2% agarose gel and samples were eval-
uated. Normal human lymphocyte DNA was either
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methylation by SssI methyltransferase(New England Bio-
labs, Ipswich, MA) to serve as unmethylated and methy-
lated controls, respectively.
Statistical analysis
Statistical analyses were performed using SPSS software
version 13.0(SPSS, Chicago, USA). Data were presented
as mean ± SD. Differences of the variables between
groups were tested by Student’s t test. P <0 . 0 5w a s
regarded as statistically significant for all the tests.
Results
Expression of WIF-1 protein
To detect the expression level of WIF-1, immunohisto-
chemistry was performed in 6 normal brain tissues and
in 53 astrocytoma tissues (Tab. 1 and Fig. 1). Reactivity
was generally cytoplasmic and membranous. The aver-
age values of WIF-1 expression were 7.33 ± 0.52 and
2.94 ± 2.19 respectively in normal brain tissues and
astrocytomas. Statistical analysis indicated that the level
of WIF-1 expression was significantly lower in tumors
than that in normal brain tissues (P <0 . 0 0 1 ) ,a n di tw a s
decreased as the pathological grade increased (P =
0.002) (Tab. 2). No significant correlation was found
between WIF-1 protein expression and age(P =0 . 5 3 ) o r
sex(P = 0.69)respectively.
Expression of WIF-1 mRNA transcript
Semiquantitative RT-PCR assay was also performed to
analyze the expression of WIF-1 at transcription level.
WIF-1 mRNA was examined in 6 normal brain tissues
as well as in 53 resected astrocytoma tissues [Tab. 1 and
Fig. 2(A)]. The results showed that WIF-1 expression in
tumor samples (0.35 ± 0.29)was significantly lower com-
pared with normal brain tissues (0.90 ± 0.06, P < 0.001).
Significant association was found between WIF-1
mRNA downregulation and the pathological grade(P=
0.001). However, WIF-1 gene expression was not corre-
lated with age(P =0 . 2 3 ) o rs e x ( P = 0.50) in tumor sam-
ples (Tab. 2).
Relationship between promoter methylation and
expression of WIF-1
To examine whether the methylation status of promoter
correlates with the expression of WIF-1, MS-PCR was
carried out [Tab. 1 and Fig. 2(B)]. No hypermethylation
was obseved in all normal brain tissues. In contrast,
aberrant methylation was observed in 29(54.72%) of 53
tumor samples. Especially, 22 (73.33%) of 30 high-grade
astrocytomas(WHO grade III, IV) showed promoter
hypermethylation.
Unmethylation-specific PCR band was detected in 9 of
29(31.03%) methylated samples, probably due to
Table 1 Patient’s clinical data and results of our study
Sample Sex Age WHO
grade
IHC
scores
mRNA Methylation
status
N1 F 60 7 0.927 U
N2 F 56 7 0.907 U
N3 M 28 7 0.862 U
N4 M 56 8 0.976 U
N5 F 27 8 0.915 U
N6 M 57 7 0.791 U
T1 M 43 II 2 0.107 U/M
T2 F 50 III 0 0 M
T3 F 38 II 5 0.653 U
T4 M 34 III 0 0 M
T5 F 57 II 2 0.658 U
T6 M 61 III 5 0.773 U
T7 M 54 IV 5 0.602 U/M
T8 M 66 IV 1 0 M
T9 F 14 I 7 0.809 U
T10 F 40 II 2 0.151 M
T11 M 37 II 5 0.462 U
T12 M 43 II 3 0.769 U
T13 F 53 II 5 0.398 U
T14 M 27 II 5 0.716 U
T15 M 45 II 5 0.722 U
T16 F 45 IV 1 0.115 M
T17 F 39 III 6 0.897 U
T18 M 30 II 3 0.215 M
T19 M 40 IV 0 0.000 M
T20 F 33 II 5 0.704 U
T21 F 38 IV 0 0.000 M
T22 M 5 II 7 0.907 U
T23 M 51 IV 1 0.000 M
T24 M 66 II 5 0.478 U
T25 F 46 II 5 0.447 U
T26 M 55 III 1 0.134 U/M
T27 M 41 III 1 0.153 U/M
T28 M 43 IV 2 0.153 M
T29 F 39 IV 1 0.129 M
T30 M 29 IV 5 0.347 U
T31 M 16 IV 0 0.000 M
T32 F 55 IV 1 0.147 M
T33 M 58 IV 2 0.189 U/M
T34 F 27 IV 1 0.131 M
T35 M 58 IV 1 0.182 M
T36 M 50 IV 3 0.122 M
T37 M 14 IV 2 0.337 U/M
T38 F 9 IV 4 0.334 U
T39 M 33 III 3 0.247 U/M
T40 F 19 III 5 0.783 U
T41 M 33 II 1 0.179 M
T42 M 38 II 2 0.164 M
T43 M 63 II 1 0.293 U/M
T44 F 37 III 2 0.158 M
T45 F 11 III 0 0.000 M
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methylation of the gene. The promoter methylated
tumors showed low WIF-1 protein and mRNA expres-
sion, whereas the promoter unmethylated tumors
displayed high protein and mRNA expression levels
(Fig. 3). Thus, these data indicated a significant correla-
tion (both P < 0.001) between hypermethylation and
decreased expression of WIF-1 in astrocytomas.
Discussion
WNT/b-catenin signaling pathway is important in
tumorigenesis and embryogenesis [15,16]. The signaling
pathway mediated by Wnt proteins currently includes
two classes - canonical and noncanonical - on the basis
of the activity of Wnt proteins in cell lines or in vivo
assays. The canonical pathway, in which b-Catenin plays
a crucial role, is the most studied Wnt pathway in can-
cers. The activation of canonical pathway allows b-cate-
nin to accumulate in the cytosol and enter the nucleus
and induces expression of Wnt target genes like c-Myc,
N-Myc, and cyclin D1 [17-19], many of which have
been implicaticated in human cancers. In astrocytoma,
the level of Wnt-2, Wnt-5a and b-catenin protein is
strikingly increased compared with normal brain tissue
[2,3,5]. Knockdown of Wnt and its key mediator b-cate-
nin in the canonical Wnt pathway by siRNA in human
astrocytoma cells inhibited cell proliferation and invasive
ability and induced apoptotic cell death, and reduced
tumorigenicity in vivo. The above findings suggest Wnt
signaling in astrocytoma is constitutively activated and
of critical importance in the astrocytoma genesis.
C  D 
B  A 
Figure 1 Selected results of immunohistochemical analysis for anti-human WIF-1 antibodies. Paraffin-embedded sections of representative
astrocytomas and normal brain tissues were stained with the antibodies against human WIF-1. The products of WIF-1 expression (brown) located
in cytoplasm and membrane. The photographs of A and B are normal brain tissues and pilocytic astrocytoma (WHO grade I)which showed
strong staining for WIF-1, respectively. In contrast, the anaplastic astrocytoma(WHO grade III) and glioblastomas(WHO grade IV)that have weak or
negative expression levels of WIF-1 were shown in C and D, respectively. Pathological malignancy grade of astrocytoma correlated with IHC
score of WIF-1.
Table 1: Patient’s clinical data and results of our study
(Continued)
T46 M 27 III 5 0.523 U
T47 F 23 IV 3 0.467 U
T48 M 27 II 0 0.176 U/M
T49 F 28 II 6 0.828 U
T50 M 25 II 2 0.332 U
T51 M 40 II 8 0.903 U
T52 M 38 II 5 0.443 U
T53 F 48 III 4 0.324 U
N, normal brain tissue; T, astrocytoma tissue ;M, male; F, female; IHC,
immunohistochemistry; U, unmethylation; M, methylation
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Figure 2 Selected results of mRNA expression and promoter methylation of WIF-1. A, RT-PCR results of the WIF-1 gene in normal brain
tissue (N1-N2) and astrocytoma (T1-T8) is shown. GAPDH is shown as a control. The fragments of amplified human WIF-1 and GAPDH cDNA
are188 and135 bp, respectively. B, Representative methylation status of the WIF-1 promoter in 10 matched pairs of normal brain tissue (N1-N2)
and astrocytomas(T1-T8).T1,3,5:WHO grade II;T2,4,6:WHO grade III;T7,8: WHO grade IV. U, unmethylated control;M, methylated control;NTC, no
template control.
Table 2 The relationship between the expression of WIF-1 and clinicopathological features in 53 cases of astrocytoma
Clinical signs Number of Cases IHC RT-PCR
Scores P-Value QT P-Value
age
<39 26 3.23 ± 2.32 0.35 0.40 ± 0.30 0.23
≥39 27 2.67 ± 2.06 0.31 ± 0.27
sex
male 32 2.84 ± 2.17 0.69 0.33 ± 0.28 0.50
female 21 3.10 ± 2.26 0.38 ± 0.31
Pathological Grading
Low grade(I - II) 23 3.96 ± 2.16 0.002
a 0.50 ± 0.27 0.001
b
High grade(III - IV) 30 2.17 ± 1.90 0.24 ± 0.25
a, b Statistically significant (p < 0.05). QT, relative mRNA level of WIF-1.
Figure 3 Correlation between hypermethylation and decreased or weak expression of WIF-1 in astrocytomas. A significant
downregulation of the protein(A) and mRNA(B) expression of WIF-1 was observed in astrocytomas with promoter methylation(both P < 0.001).
The bars in the graph showed the mean ± SD.
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tion of WIF-1 may release the inhibitory effect exerted
by WIF-1 on the WNT/b-catenin signaling[20]. This
then enhances the accumulation of b-catenin and pro-
motes tumorigenesis. Although it is known that WIF-1
is strongly expressed in embryonic mouse brain [21], its
expression in brain tumors has not yet been a matter of
investigation. In this study, we analysed the protein and
mRNA level of WIF-1 in astrocytomas using immuno-
histochemistry and RT-PCR. The level of protein and
mRNA expression in astrocytomas was significantly
lower than that in normal tissues. As the pathological
grade increased, the protein and mRNA expression of
WIF-1 gene in astrocytoma were decreased. These
results indicated that WIF-1 was frequently and signifi-
cantly downregulated in astrocytomas, especially in
high-grade astrocytomas, which might contribute to the
upregulation of Wnt/b-catenin signaling in astrocytoma
carcinogenesis.
Aberrant methylation of promoter regions that
silences transcription of the genes has been recognized
as a mechanism for inactivating tumor suppressor
genes in human cancer [22,23]. It occurs at cytosine
bases located 5’ t oag u a n o s i n ea n ds o - c a l l e dC p G
dinucleotide short regions of CpG dinucleotides known
as CpG islands are found in the proximal promoter
region of over half of human genes [23]. The methyla-
tion of these gene promoters is generally not detected
in normal tissues but in the hypermethylation of CpG
islands resulting in a loss of gene function, which is a
common feature in many tumor types. Now, many
other genes such as LHX9, MGMT, CDKN2A, PTEN,
and P15 have been shown to be methylated in astrocy-
tomas [24-28]. WIF-1 silencing may be an early epigen-
etically carcinogenic event and plays a role in tumor
development and progression[29]. In this study, we
demonstrated that WIF-1 downregulation or silencing
was associated with aberrant methylation of promoter
region in malignant astrocytoma tissue samples.
This finding reveals an important epigenetic event dur-
ing the development of astrocytoma, suggesting that
WIF-1 may be a key antagonist of Wnt signaling in
astrocytoma.
In summary, we provide evidence that WIF-1 is not
only frequently hypermethylated in astrocytomas but
this epigenetic alteration of the WIF-1 gene is associated
with reduced expression. This study reveals a novel epi-
genetic event in the pathogenesis of astrocytoma, which
may shed light on developing new approaches for this
fatal disease. The reversibility of methylation silencing
may allow restoration of WIF-1 function and regulation
of Wnt signaling. This could be important in the devel-
opment of new and effective strategy in astrocytoma
treatment.
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